Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.
The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.
advertisement
“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Deliver public health messages at the right time
Next article： New air purifier tech could be key to improving indoor air quality
Next article： New air purifier tech could be key to improving indoor air quality
